ScanGrants is a public service listing of grants and other funding types to support health research, programs and scholarship.
2 funding opportunities found in this category. Change the order of results:
Lowest Award to Highest
Highest Award to Lowest
Call for Applications: American Society of Transplantation Transplant Nursing Grant
Applications for the AST nursing grant must be submitted by Monday, September 15, 2014. The funding for this grant has been provided by the Wood-MacMillan Foundation.
2015 Transplant Nursing Research Priorities
The AST has identified the following research prioritiy for 2015, and encourages nurses working within this area to apply for funding by the AST:
Preventing late graft failure – cellular and humoral chronic rejection, recurrent and de novo GN
This is a two-year grant ($5,000/year) awarded for studies that focus on topics related to transplant candidate and recipient outcomes and well-being, quality of life, compliance, and aspects of transplant-related drugs that affect patient care (including dosing, side effects, pharmacokinetics, and pharmacogenetics). Studies should be designed to answer specific question(s). Preference will be given to prospective studies.
The AST supports a wide range of basic, clinical, and translational research topics. Research topics that involve under-represented areas including minorities, women, and pediatrics are strongly encouraged. The AST also encourages applications from women and minority researchers. Under-represented minority investigators are defined as individuals belonging to a particular ethnic or racial group as determined by the NIH. Established AST members are encouraged to bring this funding opportunity to the attention of a new faculty members performing transplantation research at their institutions and to support their applications.
Please pay particular attention to the eligbility requirements, as requirements vary for different AST grants.
Appointment and Institutional Resources: At the time of the application, the applicant must have a staff position at an accredited medical center or institution of higher learning and be an established member of the transplant team. The applicant’s Administrative Supervisor (or Chief of Transplantation) must write a letter stipulating that the applicant has the institutional resources for conducting independent research (office space, computer, statistical back-up; access to medical records) and the applicant’s Administrative Supervisor must specifically stipulate the amount of protected research time should this grant be awarded.
Membership: The applicant must be an active member of the AST or have submitted a completed membership application by September 15, 2014 (with expectation that membership will be active before the grant review occurs). The applicant's membership dues must be paid by November 1, 2014; otherwise the application will not be considered for funding.The proposed work is to be performed in a North American Medical Center.
Education: The applicant must hold a degree and have completed any advanced training commensurate with their position at the time of the application. Nurses must have sufficient advanced training and experience to perform the proposed work. Applicants can include: staff nurses (RN), nurse practitioners (RN, NP, CRNP, FNP, ACNP), and clinical nurse specialists (CNS).
Citizenship: The applicant must be either: a) US, Canadian, or Mexican citizen; b) a lawfully admitted permanent resident foreign national of the US, Canada, or Mexico with a valid visa during the award period, or c) a foreign national admitted lawfully for residence in the US, Canada, or Mexico during the awarded period. Funding will not be released until visa status is confirmed.
Previous/Additional Funding: An individual cannot apply for the AST nursing grant if he/she has been awarded an AST faculty grant in the past or if the applicant serves as the PI on a previous or current R01, project on a P01 grant, VA Merit award or comparable non-mentored award.
Michael J. Fox Foundation for Parkinson's Research Target Validation Program
Fall 2014 Review Cycle
Informational Conference Call*: March 26, 2014 at 12pm US ET
Pre-proposals Due: May 28, 2014 – 6pm US ET
Full Proposal Invitations: June 18, 2014
Full Proposals Due (by invite only): August 6, 2014 – 6pm US ET
Anticipated Award Announcement: October 2014
Anticipated Funding: November 2014
*MJFF will hold a 45-minute conference call on the dates and times listed above to clarify and explain the goals of this funding initiative and answer applicant questions. To participate in the call and receive call-in details, please RSVP via email to email@example.com.
The Target Validation program supports work to determine whether manipulation of a defined biological target provides a disease-relevant beneficial outcome in a whole animal, mammalian model of PD. MJFF does not have any pre-conceived preferences for particular targets submitted to the Target Validation program. However, we recommend applicants consider the following:
The target should be clearly defined, such as:
A specific gene
A structural/functional feature of a protein (e.g., its enzymatic activity, protein conformation or ability to interact with other proteins)
Proposals seeking to manipulate global pathways without a clear target are not encouraged
Applicants may propose a variety of methods to manipulate a target, including but not limited to:
Use of pharmacological tools
Supporting data/explanation of the proposed pharmacological tool must be addressed in the body of the proposal.
Parameters that should be discussed include:
Selectivity for the target of interest
Pharmacokinetic/Pharmacodynamic measures that have been/will be assessed
Measures of target engagement
Use of biologic strategies such as:
Viral vector-mediated gene delivery, etc.
In Vivo Models
Applicants may also propose use of models appropriate for the target proposed including:
Previously established genetically engineered animal models including:
Knockout models where the target/gene of interest is deleted
Transgenic models whereby the target/gene of interest is over-expressed
Investigators should proposed to examine PD-relevant features or sensitivity to PD-associated factors during the course of their studies
Proposals may include intermediate tests using in vitro, ex vivo and/or model organisms (e.g., Drosophila, C. elegans) to optimize the ideal target manipulation strategy
These proposals must ultimately include within the grant funding period an evaluation of the target manipulation in a whole-animal mammalian model of PD
Note: The following types of proposals are not appropriate for the Target Validation program:
Proposals focused on new target identification and proposals testing cellular transplantation approaches.
Proposals seeking to generate new genetic (knockin, knockout, transgenic) models
Investigators seeking guidance to develop new models around their target are encouraged to contact firstname.lastname@example.org
Applicants seeking support for therapeutic development should submit to the Therapeutic Pipeline Program or contact MJFF research staff for guidance.
MJFF will commit up to $10 million to the Edmond J. Safra Core Programs for PD Research with the intention to support multiple awards. The Target Validation program supports two-year grants up to $250,000 total costs inclusive of both direct and indirect costs. The total annual direct costs cannot exceed $100,000. No more than 25% (Academic institutions) or 10% (for-profit organizations) of the direct costs may go to indirect costs.
Applications may be submitted by:
U.S. and non-U.S. biotechnology/pharmaceutical companies or other for-profit entities, either publicly or privately held,
U.S. and non-U.S. entities, public and private non-profit entities, such as universities, colleges, hospitals, laboratories, units of state and local governments, and eligible agencies of the federal government.
Post-doctoral fellows are NOT eligible to apply as Principal Investigators to the Target Validation program.